Paxlovid

Paxlovid May Reduce Already Low Risk of COVID-19 Hospitalization, Death Among Vaccinated Patients

by
Paxlovid May Reduce Already Low Risk of COVID-19 Hospitalization, Death Among Vaccinated Patients

The use of nirmatrelvir plus ritonavir further (Paxlovid) reduces the already low risk of hospitalization among older vaccinated patients who contract COVID-19, found researchers of a new study published in Annals of Internal Medicine, The observational retrospective study adds insight into the use of nirmatrelvir plus ritonavir among patients who are vaccinated against COVID-19. Although … Read more

Chinese People Turn to Indian-Made Generic Drugs After Pfizer’s Paxlovid Excluded from China’s Health Insurance

by
Chinese People Turn to Indian-Made Generic Drugs After Pfizer’s Paxlovid Excluded from China’s Health Insurance

China lehnt das antivirale Medikament von Pfizer nicht ab, weil es „überteuert“ ist, wie öffentlich erklärt wird: Analyse Nachrichtenanalyse Chinesen suchen nach in Indien hergestellten Generika, nachdem Paxlovid, das antivirale COVID-19-Medikament von Pfizer, kürzlich aus Chinas staatlichem Krankenversicherungssystem ausgeschlossen wurde. Am 1. August versäumte es Chinas National Health Insurance Administration (NHSA), mit Pfizer über die … Read more

Paxlovid reduces serious risks from Omicron variants

by
Paxlovid reduces serious risks from Omicron variants

Bir Bakışta Antiviral tedavi Paxlovid, yaşlı erişkinlerde SARS-CoV-2 Omicron varyantlarından hastaneye yatma veya ölüm riskini %44 azalttı. Paxlovid’in daha geniş kullanımı, diğer bazı tedaviler artık etkili olmadığından, kış aylarında yaşanan COVID-19 artışını hafifletmeye yardımcı olabilir. Antiviral tedaviler, COVID-19’a neden olan virüs SARS-CoV-2’den ciddi hastalık ve ölüm riskini azaltmaya yardımcı olabilir. Bu, özellikle tam olarak aşılanmamış … Read more

Paxlovid Not on ‘Approved Drug List’ for China’s Health Insurance

by
Paxlovid Not on 'Approved Drug List' for China's Health Insurance

Peking — China wird Paxlovid von Pfizer Inc. nicht in eine Aktualisierung seiner Liste von Medikamenten aufnehmen, die durch grundlegende Krankenversicherungssysteme abgedeckt sind, da das US-Unternehmen einen hohen Preis für das COVID-19-Medikament angegeben hat, sagte Chinas Healthcare Security Administration (NHSA) am Sonntag. Das antivirale Medikament COVID-19 wird derzeit durch das breite Krankenversicherungssystem des Landes im … Read more